Table 1 Characteristics of primary/recurrent patient cohort and tumors

From: Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  

Breast

Ovarian

Total

Patients

 

13

14

27

Tumors

Primary

13

14

27

Recurrent

18

22

40

Total

31

36

67

Number of recurrences collected per patient

1

9

11

20

>1

4

3

7

Germline mutation

BRCA1

9

10

19

BRCA2

4

4

8

Estrogen receptor (ER) status of primary tumor

ER+

4

N/A

4

ER-

9

N/A

9

Stage at diagnosis

I

2

1

3

II

8

3

11

III

2

8

10

IV

0

1

1

Unreported

1

1

2

Treatment receiveda,b

Platinums

3

14

17

PARPic

1

4

5

Chemotherapy

13

14

27

Hormonal therapy

5

3

8

Radiation

7

3

10

  1. aTreatments are limited to reflect the number of patients from whom a post-treatment recurrence was collected.
  2. bTreatment groups are not mutually exclusive; most patients received multiple treatments.
  3. cPARPi poly (ADP-ribose) polymerase inhibitor.